phone Book Now
phone Book Now
Rockyview Health Centre, 1011 Glenmore Trail SW Building #1 Suite 423, Calgary, AB T2V 4R6, Canada
587-353-5061 Book Appointment
Mission
We are passionate about your eyes, and about building long-lasting relationships. Our goal is to ensure your eyes remain healthy throughout your life. We are all about service, love, kindness and a belief in strong community. Through our holistic approach to caring for you and our dedication to learning, we pioneer carefully researched new treatments, technology, and products to help ensure eye health.

Have you been experiencing blurred vision or an enlarging blind spot in the center of your vision, flashes or flickering of light, wavy or zigzag lines out of the corner of the eye that blocks part of their vision? You may be experiencing a Visual Aura or Ocular Migraine. These symptoms often present when working in front of a computer screen and prevent you from continuing your work. They can last up to 30 minutes affecting your central vision and then moving outwards to your peripheral vision. Ocular migraines are painless, usually visual in nature and can affect one or both eyes. If the ocular migraine is followed by a throbbing headache, this is called a Migraine with Aura and can be accompanied by light sensitivity, noise sensitivity and/or nausea.

Treatment Options

Eyedeology offers a custom lens to help provide relief from Migraines. These special lenses are tinted to block the light in the blue spectrum which can trigger a Migraine. The specific tint, FL41, has also been identified as an effective therapy for individuals with Photophobia, or an abnormal sensitivity to light. Many people with Photophobia also report an involuntary twitching of the eyelids and this condition can vary from mild to severe where incessant lid closure may cause discomfort and impair vision.

The effectiveness of the FL41 tinted lenses may vary from patient to patient, but for those suffering from Migraines, Photophobia and Blepharospasm, these lenses can help provide relief or decrease the severity of symptoms. Make an appointment for a complete eye exam and talk to our Opticians for a sample pair.

Recommendations:

Our Optometrist near you, can help review your signs and symptoms and advise of treatment options such as Botox, nutrition, vitamins and lenses to help with relief.

Coverage

As Optometrists, we can monitor patients and recommend preventative measures, follow-up with patients with Ocular Migraines, and co-manage care with Ophthalmologists and family Physicians when required.

Frequently Asked Questions

Areas We Serve

phone Call NowBook Now

Advanced Myopia Control for Children

Recent randomized controlled clinical trial results presented at the ARVO 2026 Annual Meeting showed promising results for children aged 4–12. Among the 196 children who completed the study, those wearing MiYOSMART iQ showed no average myopia progression after 12 months. The study also found that excessive axial eye growth was reduced to levels below or comparable to those seen in children without refractive errors.

Designed to Help Control Myopia Progression

Myopia, commonly known as short-sightedness, can progress during childhood as the eye grows excessively. Managing myopia earlier in life may help reduce the impact of continued progression and the associated risks of high myopia later in life.

MiYOSMART iQ builds on the established D.I.M.S. Technology used in MiYOSMART lenses and introduces a Triple Enhanced Design (TED). This design incorporates three key enhancements:

  1. Defocus Segments Closer to the Center: The segments are positioned closer to the geometric center of the lens to provide continued exposure to myopic defocus across the near-peripheral retina.
  2. Higher Defocus Power: The lens provides a stronger myopic defocus signal intended to support myopia control.
  3. Extended Treatment Zone: A larger treatment area provides broader coverage of the child’s peripheral visual field, including when larger frames are used.

Clinical Results Across Different Age Groups

The clinical trial included children between 4 and 12 years of age, with results demonstrating myopia-control efficacy across the age groups studied.

For children aged 4–6 years, MiYOSMART iQ demonstrated 65% efficacy in spherical equivalent refractive error (SER) and 44% efficacy in axial length over 12 months. For children aged 7–12 years, the lens demonstrated over 100% efficacy in SER and 94% efficacy in axial length during the same period.

The study also reported a high level of compliance with daily, all-day wear among children across the age groups studied.

Built on Established D.I.M.S. Technology

MiYOSMART iQ represents an evolution of MiYOSMART, a myopia-control lens technology backed by more than 100 peer-reviewed scientific publications. The updated lens design builds on research into how the eye responds to myopic defocus and focuses on delivering a stronger and more consistently positioned defocus signal.

Since its launch in 2018, more than 15 million MiYOSMART spectacle lenses have been purchased by parents across more than 50 countries worldwide.

Supporting Earlier Myopia Management

The clinical findings for MiYOSMART iQ include children as young as four years old, representing an important development in spectacle-lens-based myopia control. Early-onset myopia can progress during a critical period of childhood eye development, making appropriate management an important consideration for children with progressive myopia. MiYOSMART iQ provides an advanced spectacle-lens option for children who require myopia management. An eye care professional can assess your child’s vision and determine whether this type of lens is appropriate for their individual needs.
587-317-2134